¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"multiple sleep latency test"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • multiple endocrine neoplasia 1
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç1Çü
  • multiple endocrine neoplasia 2
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç2Çü
  • multiple endocrine neoplasia 3
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç3Çü
  • multiple epiphyseal dysplasia
    ¹µ»À³¡Çü¼ºÀÌ»ó, ´Ù¹ß°ñ´ÜÇü¼ºÀÌ»ó
  • multiple excitation
    ´Ù¹ßÈïºÐ
  • multiple fetation
    ´Ù¼öÀÓ½Å
  • multiple field irradiation
    ¿©·¯¿µ¿ªÁ¶»ç
  • multiple fission
    ¹µºÐ¿­, ´ÙÁߺп­
  • multiple fracture
    ´Ù¹ß°ñÀý
  • multiple infection
    º¹¼ö°¨¿°, ¿©·¯¹ø°¨¿°
  • multiple intestinal polyposis
    ´Ù¹ßÀåÆú¸³Áõ
  • multiple intussusception
    ´Ù¹ßâÀÚ°ãħÁõ, ´Ù¹ßÀåÁßøÁõ
  • multiple keratoacanthoma
    ´Ù¹ß°¢Áú°¡½Ã¼¼Æ÷Á¾
  • multiple labor
    ´Ù»ê, ´Ùźи¸
  • multiple logistic model
    ´ÙÁß·ÎÁö½ºÆ½¸ðÇü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • provocation test
    À¯¹ß°Ë»ç, À¯¹ß¹ÝÀÀ°Ë»ç
  • pulmonary function test
    Æó±â´É°Ë»ç
  • quantitative test
    Á¤·®°Ë»ç
  • reduction test
    ȯ¿ø½ÃÇè
  • renal function test
    ÄáÆÏ±â´É°Ë»ç, ½ÅÀå±â´É°Ë»ç
  • Rorschach test
    ·Î¸£»þÇϰ˻ç
  • Schilling test
    ½¯¸µ°Ë»ç
  • screening test
    ¼±º°°Ë»ç
  • secretin test
    ¼¼Å©·¹Æ¾°Ë»ç
  • sentence completion test
    ¹®Àå¿Ï¼º°Ë»ç
  • statistical test
    Åë°è°ËÁ¤
  • test tube
    ½ÃÇè°ü
  • thematic apperception test
    ÁÖÁ¦Åë°¢°Ë»ç
  • tilt test
    ±â¸³°æ»ç°Ë»ç
  • treadmill test
    Æ®·¹µå¹Ð°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • sleep activation
    ¼ö¸éȰ¼º
  • sleep apnea
    ¼ö¸é¹«È£Èí
  • sleep attack
    ¼ö¸é¹ßÀÛ
  • sleep-related sinus arrest
    ¼ö¸é°ü·Ã½ÉÀå¹Úµ¿Á¤Áö
  • breathing related sleep disorder
    È£Èí°ü·Ã¼ö¸éÀå¾Ö
  • sleep bruxism
    À̰¥ÀÌ
  • circadian rhythm sleep disorder
    ÀÏÁÖ±âÀ²µ¿¼ö¸éÀå¾Ö, ÇÏ·çÁÖ±â¼ö¸éÀå¾Ö
  • crescendo sleep
    Á¡Áõ¼º¼ö¸é
  • delayed sleep phase
    Áö¿¬¼ö¸éÀ§»ó
  • delayed sleep phase syndrome
    ¼ö¸éÀ§»óÁö¿¬ÁõÈıº
  • delta sleep
    µ¨Å¸¼ö¸é
  • sleep disorder
    ¼ö¸éÀå¾Ö, ¼ö¸éº´
  • sleep drunkenness
    Àá¿¡ÃëÇÑ»óÅÂ
  • sleep-wake schedule disorder
    ¼ö¸é°¢¼ºÀÏÁ¤Àå¾Ö
  • sleep-wake transition disorder
    ¼ö¸é°¢¼ºÀÌÇàÀå¾Ö
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Cuboni s test
    Äíº¸´Ï½ÃÇè.
  • Cytronbergs test
    ½ÃÆ®·Ðº£¸£Å©½ÃÇè.
  • DAT =>direct antiglobulin test
    Á÷Á¢ Çױ۷κҸ°½ÃÇè
  • DDST=Denver developmental screening test
    µ§¹ö¹ß´ÞÁ¶»ç°Ë»ç
  • DNase test
    DNA ºÐÇØÈ¿¼Ò½ÃÇè
  • DST=dexamethasone supression test
    µ¦»ç¸ÞŸ¼Õ ¾ïÁ¦°Ë»ç
  • Dehydration test
    Å»¼ö°Ë»ç
  • Denver Developmental Screening Test
    µ§¹ö¹ß´ÞÁ¶»ç°Ë»ç(Û¡Ó¹ðàÞÛËþÞÛ)
  • Denver developmental screening test
    µ§¹ö¹ßÀ°¼±º°¹ý.
  • Dick test
    µñÅ©½ÃÇè
  • Dick test
    µñ °Ë»ç
  • Donath-Landsteiner test
    µµ³ª¾²¶õÆ®½ºÅ¸ÀÌ³Ê °Ë»ç
  • Draw-A-Person test(DAP)
    Àι°È­°Ë»ç
  • Du test
    Du °Ë»ç (ÁÖÀÇ : u ´Â À­Ã·ÀÚÀÓ)
  • Eleks gel-precipitin test
    ¿¤·ºÅ©ÇÑõÆòÆÇħ°­¹ý (µðÇÁÅ׸®¾Æµ¶¼Ò µ¿Á¤¹ý)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • sleep habits
    Àá¹ö¸©
  • sleep hygiene
    ¼ö¸éÀ§»ý
  • sleep hyperhidrosis
    ¼ö¸é¹ßÇÑÁõ
  • sleep hypochondriasis
    ¼ö¸é½É±âÁõ (¡­ãýѨñø).
  • sleep inertia, excessive
    °úµµÇÑ ¼ö¸é¹«·ÂÁõ
  • sleep modified disorder
    ¼ö¸éº¯ÇüÀå¾Ö(º´)
  • sleep movement
    ¼ö¸é¿îµ¿(â²Øùê¡ÔÑ).
  • sleep paralysis
    ¼ö¸é¸¶ºñ(¡­ Ýö).
  • sleep paralysis
    ¼ö¸é¸¶ºñ(¡­Ø¦Ýö)
  • sleep phase advance
    ¼ö¸éÀ§»óÀüÁø
  • sleep position restriction
    ¼ö¸éÀÚ¼¼Á¦ÇÑ
  • sleep promoting substance(SPS)
    ¼ö¸éÁõÁø¹°Áú
  • sleep restriction therapy
    ¼ö¸éÁ¦ÇÑ¿ä¹ý
  • sleep seizure
    ¼ö¸é¼º ¹ßÀÛ
  • sleep spindle
    ¼ö¸é¹æÃß(-ü, »ç, ÆÄ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • phase test
    »ó½ÃÇè(ßÓãËúÐ)
  • phenolsulfonphthalein test
    Æä³î¼³ÆùÅ»·¹ÀÎ ½ÃÇè(ãËúÐ)
  • phenylalanine load test
    Æä´Ò¾Ë¶ó´Ñ ºÎÇϽÃÇè(ݶùÃãËúÐ)
  • phenylalanine tolerance test
    Æä´Ò¾Ë¶ó´Ñ ³»¼º½ÃÇè(Ò±àõãËúÐ)
  • PSP test
    (å²) Phenolsulfonphthalein test
  • radioactive antibody test
    ¹æ»ç¼º Ç×ü ½ÃÇè(°ËÁ¤)(Û¯ÞÒàõù÷ô÷ãËúÐ(ËþïÒ))
  • resorcinol test
    ¸®Á¶¸£½Ã³î ½ÃÇè(ãËúÐ)
  • reversible boundary spreading test
    °¡¿ª °æ°è ºÐ»ê ½ÃÇè(ʦæ½ÌÑÍ£ÝÂߤãËúÐ)
  • Rice test
    ¶óÀ̽º ½ÃÇè(ãËúÐ)
  • ring test
    °í¸®½ÃÇè(ãËúÐ)
  • Rothera's test
    ·ÎÅ×¶ó ½ÃÇè(ãËúÐ)
  • Schiff's test
    ½¬ÇÁ ½ÃÇè(ãËúÐ)
  • Schilling test
    ½¯¸µ ½ÃÇè(ãËúÐ)
  • seliwanoff's test
    ¼¿¸®¹Ù³ëÇÁ ½ÃÇè(ãËúÐ)
  • SSA test
    SSA ½ÃÇè(ãËúÐ) (å²)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MCS malignant carcinoid syndrome; managed care system; massage of the carotid sinus; mesocaval shunt; me...
BS Bachelor of Science; Bachelor of Surgery; Bacillus subtilis; Bartter syndrome; base strap; bedside; ...
SPT secretin-pancreazymin [test]; single patch technique; sleep period time; spectrin; station pull-thro...
TS Takayasu syndrome; Tay-Sachs; temperature sensitivity; temperature, skin; temporal stem; tensile str...
AL absolute latency; acinar lumen; acute leukemia; adaptation level; albumin; alcoholism [and other dru...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
E test Epsilometer test
AS Active Sleep
CSA Central sleep apnea
DSPS Delayed Sleep Phase Syndrome
DSIP Delta Sleep Inducing Peptide
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • multiple sinus fracture
    ´Ù¹ß¼º ºÎºñµ¿ °ñÀý
  • multiple somatic receptor
    ´Ù¹ß¼º ü ¼ö¿ëü, ´Ù¹ß¼º ü ¼ö¿ë±â
  • multiple spike
    ´Ù¹ß¼º ½ºÆÄÀÌÅ©
  • multiple surgical procedure
    ´Ù¹ß¼º ¿Ü°úÀû Ä¡·á
  • multiple vascular tumor
    ´Ù¹ß¼º Ç÷°ü Á¾¾ç
  • multiple wart
    ´Ù¹ß¼º »ç¸¶±Í
  • multiple-loop wiring
    ¿¬¼Ó Ä¡¾Æ °áÂû¹ý
  • single-factor versus multiple-factor analysis
    ´ÜÀÏ ¿ä¼Ò ºÐ¼® ´ë º¹ÇÕ ¿ä¼Ò ºÐ¼®
  • abrasion test
    ¸¶¸ê ½ÃÇè
    ¸¶¸ð¿¡ °ßµð´Â Á¤µµ¸¦ ½ÃÇèÇÏ´Â °Ë»ç.
  • acetest tablet test
    ¾Æ¼¼Å×½ºÆ® Á¤ ½ÃÇè
    ¹éÁö À§¿¡ ¿Ã·Á³õÀº ¾Æ¼¼Å×½ºÆ® Á¤¿¡ ¿ä ÇÑ ¹æ¿ïÀ» ¶³¾î¶ß¸± ¶§, ¾î´À Á¤µµÀÇ ¾Æ¼¼ÅæÀÌ Á¸ÀçÇÏ¸é ±× ¾ç¿¡ µû¶ó¼­ ¾Æ¼¼Å×½ºÆ® Á¤ÀÌ ´ãÀÚ»ö
  • acetoacetic acid test
    ¾Æ¼¼Åä ÃÊ»ê ½ÃÇè
  • achievement test
    ¼öµæ´É·Â °Ë»ç, ¼öµæ´É·Âµµ °Ë»ç
  • acid elution test
    »ê ¿ë¸® ½ÃÇè
    ÅÂ¾Æ Çì¸ð±Û·ÎºóÀÇ °ËÃâ ½ÃÇèÀ¸·Î, ½½¶óÀÌµå ±Û¶ó½º À§¿¡ °ø±â °ÇÁ¶µÈ Ç÷¾× µµÆ÷ Ç¥º»À» 80% ¸ÞŸ³î·Î °íÁ¤ÇÏ¿©,
  • acoustic reflex test
    û°¢¹Ý»ç ½ÃÇè
    û°¢¹Ý»ç ¿ªÄ¡ÀÇ ÃøÁ¤¹ýÀ¸·Î¼­ Àüµµ¼º°ú °¨°¢½Å°æ¼º ³­Ã»À» °¨º° Áø´ÜÇϰųª û½Å°æÁ¾À» Áø´ÜÇÏ´Â µ¥ ÀÌ¿ëµÈ´Ù.
  • ACTH stimulation test
    ACTH ÀÚ±Ø °Ë»ç
    Çϼöü ºÎ½ÅÇÇÁú°è ¿¹ºñ·Â°Ë»çÀÇ Çϳª. ºÎ½ÅÇÇÁúÀÚ±Ø È£¸£¸ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
multiple endocrine neoplasia type 2 <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
(27 Sep 1997)
multiple endocrine neoplasia type 2a A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands.
(12 Dec 1998)
multiple endocrine neoplasia type 2b A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas.
(12 Dec 1998)
multiple epiphysial dysplasia A dominantly inherited abnormality of epiphyses characterised by difficulty in walking, pain and stiffness of joints, stubby fingers, and often dwarfism of short-limb type; on X-ray examination, the epiphyses are mottled and irregular; ossification centres are late in appearance and may be multiple, but the vertebrae are normal. There is also an autosomal recessive form .
Synonym: dysplasia epiphysialis multiplex.
(05 Mar 2000)
multiple exostosis A disturbance of enchondral bone growth in which multiple, generally benign osteochondromas of long bones appear during childhood, commonly with shortening of the radius and fibula; the ill-effects are usually mechanical but malignant change is rare; autosomal dominant inheritance.
Synonym: diaphysial aclasis, hereditary deforming chondrodystrophy, multiple exostosis, osteochondromatosis.
(05 Mar 2000)
multiple fission Division of the nucleus, simultaneously or successively, into a number of daughter nuclei, followed by division of the cell body into an equal number of parts, each containing a nucleus.
(05 Mar 2000)
multiple fracture Fracture at two or more places in a bone.
See: segmental fracture.
Fracture of several bones occurring simultaneously.
(05 Mar 2000)
multiple gestation <radiology> Incidence: 1% of all births, twins in 1:85; triplets in 1:85x85; etc, uterus large for dates, may have elevated hCG, hPL, and aFP, at risk for IUGR: monochorionic-monoamniotic more than , monochorionic-diamniotic more than , dichorionic-diamniotic findings: 2 placentas indicate dichorionic-diamniotic, 1 placenta indicates monochorionic pregnancy or dichorionic pregnancy with fused placenta, separating membranes confirms diamniotic pregnancy
(12 Dec 1998)
multiple glandular deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple hamartoma syndrome Hypertrichosis and gingival fibromatosis from infancy, accompanied by postpubertal fibroadenomatous breast enlargement; papules of the face are characteristic of multiple trichilemmomas.
Synonym: multiple hamartoma syndrome.
(05 Mar 2000)
multiple idiopathic haemorrhagic sarcoma <oncology, tumour> A type of vascular cancer characterised by soft purple nodules that usually develop first on the feet and then slowly spread across the skin.This cancer is most often found in people with compromised immune systems, such as AIDS patients.
(09 Oct 1997)
multiple infection <epidemiology> An infection in which an individual is infected by parasites of more than one species.
(05 Dec 1998)
multiple intestinal polyposis Begins usually in late childhood; polyps increase in numbers, causing symptoms of chronic colitis, and carcinoma of the colon almost invariably develops in untreated cases; autosomal dominant inheritance. In the Gardner syndrome there are extracolonic changes (desmoid tumours, etc.).
Synonym: polyposis coli.
Hamartomatous polyposis of the small or large intestine, Peutz-Jeghers syndrome with melanin spots on the lips, less common, miscellaneous, rare, and doubtful occurrences.
Synonym: familial intestinal polyposis.
(05 Mar 2000)
multiple lentigines syndrome <syndrome> An autosomal dominant inherited disorder characterised by freckle-like spots (lentigines) on the trunk. Other findings may include wide set eyes, sternum abnormalities, prominent ears, deafness, cafe-au-lait spots, pulmonary stenosis, cryptorchidism, delayed puberty or hypogonadism. There is no treatment available only underlying management of each problem.
Inheritance: autosomal dominant.
(27 Sep 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • screen test
    ¿µÈ­ ¹è¿ìÀÇ Àû¼º(¹è¿ª) ½É»ç
  • skin test
    ÇǺΠ½ÃÇè
  • test
    Å×½ºÆ®;°Ë»ç;½ÃÇè(put to the ~ ½ÃÇèÇÏ´Ù);½ÃÇè¹°;½Ã¾à;½Ã±Ý¼®;stand the ~ ÇÕ°ÝÇÏ´Ù;½ÃÇè¿¡ °ßµð´Ù
  • test
    °Ë»ç(½ÃÇè)ÇÏ´Ù
  • test ban
    ÇÙ½ÇÇè ±ÝÁö ÇùÁ¤
  • test bed
    (Ç×°ø±â ¿£Áø µîÀÇ) ½ÃÇè´ë
  • test case
    Å×½ºÆ®ÄÉÀ̽º;ù½Ãµµ;½Ã¼Ò
  • test paper
    ½ÃÇèÁö
  • test patten
    ½ÃÇè ¹æ¼Û¿ë µµÇü
  • test pilot
    (½ÅÁ¶±âÀÇ) ½ÃÇè Á¶Á¤»ç
  • test tube
    ½ÃÇè°ü
  • truefalse test
    Á¤¿À ¹®Á¦
  • tuberculin test
    Åõº£¸£Ä𸰠¹ÝÀÀ °Ë»ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á